10 Best Cell and Gene Therapy Companies for Global Buyers

Choosing a cell gene therapy partner is not like selecting a standard pharmaceutical supplier. The decision can shape development timelines, manufacturing readiness, and patient access. Buyers need to look beyond compelling science. They must assess clinical evidence, production capacity, quality systems, and experience across regions.

The field is moving from promise toward carefully measured delivery. The U.S. Food and Drug Administration reported more than 30 approved cellular and gene therapy products as of 2024. Its approved-products list offers buyers a useful way to verify commercial experience. The Alliance for Regenerative Medicine’s 2024 annual report also tracks company, clinical, and investment activity across the sector. These sources matter because pipeline size alone can conceal practical gaps. A therapy may look impressive on a slide, yet still face manufacturing or scale-up challenges.

The science is personal, too. Penn immunologist Carl June has described CAR T cells as “a living drug,” capturing how these therapies can act inside the body. But that promise does not remove the need for scrutiny. Buyers should ask who controls the process, how product consistency is measured, and what support continues after treatment begins. Details matter. This guide compares ten companies through those buyer-focused questions, while recognizing that no single provider suits every program. The evidence is still evolving, and some capabilities are harder to compare than marketing materials suggest. That uncertainty deserves a place in any serious evaluation.

10 Best Cell and Gene Therapy Companies for Global Buyers
Table of Contents [Hide]
1 Define Cell and Gene Therapy Through the FDA’s Product Framework
2 Size the Sector: Grand View Research Forecasts 21.8% CAGR, 2024–2030
3 Profile 10 Global Companies by Therapy Type, Scale, and Reach
4 Compare Suppliers by GMP Manufacturing Capacity and Regulatory Footprint
5 Assess Global Buyer Needs: Access, Delivery, and Long-Term Follow-Up

Define Cell and Gene Therapy Through the FDA’s Product Framework

For global buyers, cell and gene therapy is not a single FDA product category. The agency considers what a product contains, how it is processed, and its intended use. A vial of living cells may follow a different regulatory pathway from a vector carrying genetic material. That distinction shapes evidence requirements, manufacturing controls, and premarket review. The US framework is not a universal approval system; other markets assess products under their own rules.

Some human cell and tissue products may qualify for regulation solely under section 361 if they meet specific criteria, including minimal manipulation and homologous use. Other products are regulated under section 351 as biological products and generally require FDA licensure before marketing. Gene therapies are typically regulated as biological products, but classification depends on the product’s design and use. Details matter. Even a processing change may affect the regulatory analysis.

When comparing suppliers, ask for the stated FDA pathway and supporting documentation. “FDA registered” does not mean FDA approved. Review manufacturing controls, chain-of-identity procedures, potency testing, and clinical evidence relevant to the intended use. Check cold-chain records, too; a small temperature excursion can matter. A checklist helps, but it can miss context. Product classifications and evidence may change as designs or intended uses evolve, so verify important claims and record unresolved questions before making a sourcing decision.

Size the Sector: Grand View Research Forecasts 21.8% CAGR, 2024–2030

Grand View Research forecasts a 21.8% compound annual growth rate for the global cell and gene therapy market from 2024 through 2030. That signals rapid expansion, not guaranteed returns. The estimate reflects growing research and clinical development, alongside demand for treatments aimed at underlying disease mechanisms. Yet a market forecast is not a measure of patient access. Manufacturing a single therapy can require carefully controlled batches, specialized facilities, and cold-chain shipping. Small process changes can affect quality and cost.

The U.S. Food and Drug Administration’s approved-products overview lists more than 30 cellular and gene therapy products. That shows the field has moved beyond research alone, but approval does not ensure broad availability. For global buyers, country-specific pathways, reimbursement, and treatment-center capacity can shape adoption as much as science does. Market reports also depend on definitions: some group cell, gene, and related therapies differently. So treat the 21.8% figure as a directional forecast, not a precise promise. The growth story is compelling. The practical constraints deserve equal attention.

Profile 10 Global Companies by Therapy Type, Scale, and Reach

A useful profile of ten global cell and gene therapy companies should compare what they actually make, not just their headlines. Some focus on modified immune cells, while others develop stem-cell treatments or gene therapies for inherited conditions. A few concentrate on manufacturing and testing rather than discovering treatments. These differences shape timelines, facility needs, and the expertise buyers must assess.

Scale matters, but it is not a simple measure of quality. A large manufacturer may operate multiple sites and serve several regions, while a smaller specialist may offer deeper experience with one complex process. Buyers can examine production capacity, quality systems, clinical-stage programs, and experience transferring processes between facilities. Look for concrete details: batch sizes, cold-chain arrangements, release testing, and documented supply regions. Small details matter.

Reach also needs careful interpretation. A company may have international partnerships without supplying products everywhere. Public disclosures can show where trials, manufacturing sites, or commercial operations are active, but these measures are not interchangeable. Compare the ten profiles by therapy type, operational scale, and demonstrated reach, then check each claim against current company and regulator information. The categories will overlap. That is part of the difficulty, and a neat ranking can hide meaningful differences.

Compare Suppliers by GMP Manufacturing Capacity and Regulatory Footprint

Global buyers comparing cell and gene therapy suppliers should assess usable GMP capacity, not headline output. Ask how many qualified suites support the required process, and whether production slots match your development timeline. Cell processing may depend on skilled manual work, while vector programs require different equipment and controls. Capacity matters. Check suite availability, batch-size limits, cryogenic storage, and backup plans for equipment failure. A large facility does not automatically mean timely access.

Regulatory footprint should be assessed site by site. Request current certifications, inspection records, and the scope of each quality system. Confirm which markets the supplier has experience serving, and whether its documentation supports local submissions and product release. Details matter. Review deviation handling, assay validation, change control, and chain-of-identity procedures. Ask who owns technology transfer and how process changes are communicated. A broad geographic presence can look reassuring on paper, but it may not show which facility will make your product. Comparing suppliers is imperfect; public information rarely reveals actual production availability or the quality of day-to-day collaboration. Verify critical claims directly with quality and manufacturing teams.

Assess Global Buyer Needs: Access, Delivery, and Long-Term Follow-Up

Global buyers should assess access before comparing a cell or gene therapy provider’s capabilities. Access comes first. Ask which patients may qualify, what diagnostic tests are required, and where treatment can be delivered. Eligibility rules and care pathways vary by country, so confirm local requirements with qualified clinical and regulatory advisers. A therapy may require a specialist center, trained staff, and tightly managed transport. Check how temperature is monitored, who handles delays, and whether the treatment site can receive the product on schedule. These details affect real-world access, not just procurement plans.

Delivery planning should include the patient’s full journey, from referral and testing through treatment and follow-up. Ask who coordinates appointments, communicates with caregivers, and responds if a patient’s condition changes. Long-term follow-up needs clear schedules, named clinical contacts, secure records, and a process for reporting health changes. Plans can change. Buyers should check how follow-up remains practical when patients live far from treatment centers or move between health systems. No checklist catches everything; even a well-designed plan may overlook the strain of repeated travel on families. A transparent provider should explain limits, responsibilities, and support options before treatment begins.

10 Best Cell and Gene Therapy Companies for Global Buyers - Assess Global Buyer Needs: Access, Delivery, and Long-Term Follow-Up

A buyer-focused comparison of ten established cell and gene therapy programs

Scope: Company and brand identifiers are omitted. Entries use nonproprietary therapy names and are selected as representative programs, not as a ranked list of suppliers. Marketing authorization, eligible populations, and availability vary by jurisdiction.

Therapy program Modality Principal approved use Access and jurisdiction considerations Delivery and operational needs Long-term follow-up considerations
Tisagenlecleucel Autologous CD19-directed CAR T-cell therapy Selected B-cell malignancies, including certain forms of acute lymphoblastic leukemia and lymphoma. Authorized in the United States and European Union for specified patient groups. Age limits, disease settings, and prior-treatment requirements are label-specific. Requires patient-specific cell collection, manufacturing, and return shipment. Treatment is delivered at qualified centers prepared to manage serious immune-related complications. Follow the applicable product label and care protocol; monitor for delayed adverse events and ongoing treatment-related risks.
Axicabtagene ciloleucel Autologous CD19-directed CAR T-cell therapy Selected aggressive B-cell lymphomas and follicular lymphoma in eligible adults. Authorized in the United States and European Union for specified indications. Eligibility and treatment-line criteria differ by label. Requires individualized manufacturing and specialized center capacity, including monitoring and management of cytokine release syndrome and neurologic toxicity. Long-term monitoring should follow the current label and local clinical protocol, including surveillance for delayed complications.
Lisocabtagene maraleucel Autologous CD19-directed CAR T-cell therapy Selected B-cell malignancies, including certain adult lymphomas; specific indications vary across markets. Authorized in the United States and European Union for defined populations. Buyers should verify the current local label and reimbursement criteria. Requires leukapheresis, patient-specific manufacturing, and treatment at a center able to provide specialist monitoring and urgent supportive care. Use the relevant market’s label and follow-up plan; monitor for both early toxicities and delayed treatment-related events.
Idecabtagene vicleucel Autologous BCMA-directed CAR T-cell therapy Relapsed or refractory multiple myeloma in eligible patients after prior therapies. Authorized in the United States and European Union for specified patient groups. Required prior treatments and eligibility criteria are jurisdiction-specific. Personalized cell collection and manufacturing require advance scheduling and coordination of bridging treatment, where clinically appropriate. Monitor response durability, blood counts, infections, and delayed adverse events according to the applicable label and care plan.
Ciltacabtagene autoleucel Autologous BCMA-directed CAR T-cell therapy Relapsed or refractory multiple myeloma in eligible patients after prior therapies. Authorized in the United States and European Union for defined populations. Local labels and access pathways should be checked before referral. Requires patient-specific cell collection and manufacturing, plus experienced center capacity for infusion and post-infusion monitoring. Follow the product-specific monitoring plan, including observation for delayed neurologic effects and other late complications.
Lifileucel Autologous tumor-infiltrating lymphocyte cell therapy; not gene-modified Unresectable or metastatic melanoma in a defined adult population after prior systemic treatment. Authorized in the United States for a specified indication. Availability and regulatory status elsewhere must be confirmed locally. Requires tumor-tissue procurement, individualized manufacturing, lymphodepleting chemotherapy, and specialist inpatient care for treatment and supportive therapy. Requires standard oncologic follow-up and monitoring for complications associated with the cell therapy and accompanying treatment regimen.
Exagamglogene autotemcel Autologous, gene-edited hematopoietic stem-cell therapy Eligible patients with sickle cell disease or transfusion-dependent beta thalassemia. Authorized in the United States, European Union, and United Kingdom for specified populations. Age and disease criteria vary by jurisdiction. Requires stem-cell collection, individualized manufacturing, myeloablative conditioning, and care at a specialist transplant center. Long-term follow-up is important for safety and durability assessment; the care plan should address blood-cell recovery and conditioning-related risks.
Onasemnogene abeparvovec One-time adeno-associated virus (AAV) gene-replacement therapy Spinal muscular atrophy in patient groups defined by the local label. Authorized in multiple jurisdictions, including the United States and European Union. Age, weight, clinical, and testing criteria differ across labels. Administered as an intravenous infusion. Delivery requires specialist assessment and monitoring, including liver-related laboratory checks and other label-directed precautions. Requires structured follow-up after administration, including monitoring for safety and persistence of clinical benefit under the local protocol.
Voretigene neparvovec AAV gene-replacement therapy delivered to the retina Inherited retinal dystrophy associated with confirmed biallelic RPE65 mutations and viable retinal cells. Authorized in the United States and European Union for appropriately diagnosed patients. Genetic confirmation and specialist eligibility assessment are essential. Requires ocular surgery by a suitably experienced retinal specialist; treatment is delivered separately to each eye according to the approved protocol. Ophthalmic follow-up is needed to assess vision-related outcomes and monitor for procedure- or treatment-related complications.
Etranacogene dezaparvovec AAV gene therapy for hemophilia B Hemophilia B in eligible adults, subject to local label criteria. Authorized in the United States and European Union. Eligibility may depend on disease severity, antibody testing, and other jurisdiction-specific requirements. Administered as a one-time intravenous infusion after specialist assessment. Buyers should plan for pre-treatment testing and access to hemophilia expertise. Ongoing monitoring of factor activity, bleeding outcomes, liver health, and treatment durability is part of long-term care.

Buyer note: Regulatory approvals do not guarantee local supply, reimbursement, or treatment-center capacity. Confirm current national product information, eligibility criteria, referral pathways, cold-chain or cell-shipping requirements, and follow-up obligations before planning access.

Blog Tags:

© 2022 - Krishgen Biosystems. All Rights Reserved | Privacy Policy